In chronic-phase chronic myeloid leukemia, treatment-free remission (TFR) after tyrosine kinase inhibitor therapy has become, with survival, a primary goal for virtually all patients.

The possibility of achieving TFR can no longer be denied to any patient, but some issues regarding the optimal selection of candidates remain unsolved.

We provide practical tools intended to facilitate the decision-making process and maximize the rate of TFR.